DNAnexus Valuation, Funding & Investors
DNAnexus is valued at $600M as of March 2022.
Last DNAnexus valuation
$600M
Series H · Mar 2022
Last DNAnexus funding round
$200M
Series H · Mar 2022
Cumulative funding DNAnexus raised
$456M
across 6 funding rounds
Key investors in DNAnexus
GV
TPG
Foresite Capital
Claremont Creek Ventures
First Round Capital
Perceptive Advisors
About DNAnexus
DNAnexus is a Mountain View-headquartered cloud platform for genomic data management and analysis. Founded in 2009, the company supports petabyte-scale storage, HIPAA-compliant collaboration, and AI workflows for clients including the Broad Institute, Illumina, and NHS Genomics England. DNAnexus operates data centers in the US, Europe, and Asia, powering projects like the UK Biobank analysis and COVID-19 surveillance. Its Apollo system enables secure multi-tenant research across 100,000 genomes.
Founded
2009
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Subscription, Usage-based
Valuation
$600M (Mar 2022)
DNAnexus Valuation
DNAnexus is currently valued at $600M, based on its Series H in March 2022.
The $200M round was led by Blackstone, with participation from Northpond Ventures, GV, Innovatus Capital Partners, Foresite Capital and Perceptive Advisors.
DNAnexus valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2022 | Series H | $600M |
DNAnexus Funding History
DNAnexus has raised a total of $456M across 6 funding rounds.
DNAnexus' first fundraising round was a $15M Series C in January 2014. The most recent completed round was a $200M Series H in March 2022.
DNAnexus funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2022 | Series H | Blackstone (lead); Northpond Ventures; GV; Innovatus Capital Partners; Foresite Capital; Perceptive Advisors | $200M | $600M | DNAnexus, a Mountain View, California-based provider of cloud-based biomedical data analysis software, secured a $200 million Series I financing round on March 8, 2022, led by funds managed by Blackstone Growth, with participation from existing investors Northpond Ventures, GV (Google Ventures), Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital. The round valued the company at approximately $600 million, according to the Silicon Valley Business Journal. The funding aims to accelerate the global adoption of DNAnexus's Precision Health Data Cloud platform, which enables life sciences organizations to analyze complex multi-omics and clinical data for precision medicine applications. At the time of the financing, DNAnexus served over 12,000 platform users across 48 countries, including seven of the top 10 pharmaceutical companies and eight of the top 10 diagnostics firms as customers. The platform managed more than 65 petabytes of data, growing at 70% annually since 2015, amid projections of over 500 million genomes sequenced by 2025, generating 40 exabytes of data. CEO Richard Daly highlighted the investment's role in advancing the product roadmap to meet demand for biomedical data technologies. Post-funding, DNAnexus expanded its leadership team, appointing Stephen Nuckols as Chief Commercial Officer to drive commercial growth, sales, and marketing. Blackstone has supported operational enhancements, including data infrastructure expansion and board strengthening. The company has continued partnerships, such as with Veeva for regulatory collaboration, UK Biobank for genomic data releases, and others like Twist Bioscience and Curio Bioscience for NGS and spatial transcriptomics workflows. In 2024, DNAnexus received a Frost & Sullivan award for enabling technology leadership in bioinformatics-based drug discovery. |
| Jun 2020 | Series G | Northpond Ventures (lead); Perceptive Advisors (lead); First Round Capital; GV; Regeneron; Foresite Capital; TPG | $100M | - | DNAnexus is a cloud-based SaaS platform for genomic and clinical data management, analysis, and insights, serving the global life science community to accelerate precision medicine. The company completed a $100 million Series G (or H per some sources) funding round on June 9, 2020, co-led by Perceptive Advisors and Northpond Ventures, with participation from GV (Google Ventures), Foresite Capital, TPG Capital, First Round Capital, and new investor Regeneron Pharmaceuticals. This was the largest round to date for DNAnexus, bringing total funding to about $227 million at that point, aimed at supporting global growth, market expansion, digital transformation, and scaling for healthcare and life science organizations. At the time, DNAnexus powered major customers including eight of the top 10 clinical diagnostics companies and seven of the world's biggest pharmaceutical companies, processing 10 million core hours monthly and storing 28 petabytes of data with 70% annual growth over the prior four years. The platform simplifies complex data analysis and clinical data management at unprecedented scale, positioning DNAnexus as a leader in integrating clinical and genomic data for biomedical R&D and diagnostics. Investors highlighted the company's rapid growth velocity, customer breadth, innovation, and role in a precision medicine market projected to exceed $119 billion by 2026. Subsequent developments include a $200 million Series I round in March 2022 from Blackstone, GV, Northpond, Perceptive, and others, reportedly valuing the company at around $600 million, further expanding AI/ML tools and international presence to over 12,000 users in 48 countries managing 65+ petabytes of data. |
| Feb 2019 | Series F | GV; Innovatus Capital Partners; Genuity Science; Claremont Creek Ventures; Foresite Capital; TPG | $68M | - | DNAnexus, a biomedical informatics and data management platform founded in 2009 by Stanford alumni, raised $68 million in a financing round closed around February 6, 2019, from existing investors GV (formerly Google Ventures), Foresite Capital, TPG Biotech, WuXi NextCODE, and Claremont Creek Ventures, plus debt and equity from Innovatus Capital Partners. The round brought total funding to approximately $173 million, following a $58 million raise in January 2018 led by Foresite Capital. The platform provides cloud-based solutions for analyzing massive volumes of DNA sequencing data, integrating genomic data with clinical and phenotypic information, and enabling secure collaboration for researchers, supporting projects like the NIH’s All of Us initiative. Proceeds supported deployment of DNAnexus Apollo, an advanced platform for multi-omics and clinical data exploration, analysis, and discovery, accelerating biopharma workflows from target identification to clinical development. The company positions itself to address growing demands in genomics research, clinical diagnostics, and trials by offering compliant infrastructure and access to tools/datasets via a global network. DNAnexus serves large-scale genomic projects and collaborates with entities like Microsoft on St. Jude Cloud. The company expanded internationally with offices in San Francisco, London, and Prague, employing around 66 people by mid-2020. |
| Jan 2018 | Series E | Foresite Capital (lead); Microsoft; GV; MidCap Financial; Genuity Science; Claremont Creek Ventures; TPG | $58M | - | DNAnexus is a Mountain View, California-based provider of biomedical informatics and data management software. The company operates a global, cloud-based platform designed for researchers in clinical diagnostics, biopharma, bioagriculture, and government sectors. Through its platform, scientists can manage, access, and analyze genomic and biomedical sequencing data, enabling organizations to improve their genomics programs and advance precision medicine research. In January 2018, DNAnexus closed a $58 million financing round led by Foresite Capital, with strategic investment from Microsoft and participation from existing investors GV (formerly Google Ventures), TPG Biotech, WuXi NextCODE, MidCap Financial, and Claremont Creek Ventures. The capital was designated to support the development and launch of translational medicine solutions, expansion in clinical trials, and broadened use of biomedical data across the organization's global network. At the time of the round, DNAnexus had built significant traction in the precision medicine and genomics sectors. The company was supporting some of the largest human genome sequencing projects in the world and had established partnerships with leading research institutions. The platform was already serving customers across multiple countries and domains. DNAnexus subsequently raised additional funding, including a $68 million round in February 2019 from existing investors and Innovatus Capital Partners, and a $100 million round in June 2020 led by Perceptive Advisors and Northpond Ventures. The company later secured $200 million in funding led by Blackstone Growth, which valued the company at approximately $600 million and brought total lifetime financing to nearly $475 million at that point. |
| Apr 2015 | Series D | Wuxi AppTec (lead) | $15M | - | DNAnexus, a California-based company offering cloud-based storage and analysis of genetic data, received a $15 million strategic investment from WuXi PharmaTech in a Series D round around April 2015. The investment accompanied a partnership where WuXi's NextCODE subsidiary collaborated with DNAnexus to integrate its informatics and data management technology, expanding access in China. WuXi CEO Ge Li highlighted the alliance as combining top technologies for global genomics applications, from sequencing to drug discovery and companion diagnostics. |
| Jan 2014 | Series C | Claremont Creek Ventures (lead); First Round Capital (lead); GV (lead); TPG (lead) | $15M | - | DNAnexus, a US-based provider of a cloud-based genomic analysis platform, closed a $15 million Series C funding round in early 2014 led by Claremont Creek Ventures, Google Ventures (GV), TPG Biotech, and First Round Capital. The platform offers a Platform-as-a-Service (PaaS) for managing large-scale DNA data, enabling collaboration, secure storage, and compliant analysis pipelines supporting HIPAA, CLIA, and international regulations. The funding aimed to expand capacity for commercial and academic labs worldwide and accelerate commercialization. DNAnexus had demonstrated traction through large-scale projects, including partnerships with Stanford University and Baylor College of Medicine. These initiatives processed over 17,000 genomes and generated more than 500 terabytes of genomic data, made available for researchers in the 1000 Genomes Project and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, which sequenced nearly 4,000 whole genomes and over 10,000 whole exomes. |
Who has invested in DNAnexus?
14 investors have backed DNAnexus across its funding rounds, including GV, TPG, Foresite Capital, Claremont Creek Ventures, First Round Capital and Perceptive Advisors.
Lead investors include Blackstone, Northpond Ventures, Perceptive Advisors, Foresite Capital, Wuxi AppTec and 4 other investors.
DNAnexus Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 5 | Lead | Jan 2014 | |
| San Francisco, CA | 4 | Lead | Jan 2018 | |
| San Francisco, CA | 4 | Lead | Jan 2014 | |
| San Francisco, CA | 3 | Lead | Jan 2014 | |
| Washington, DC | 2 | Lead | Jun 2020 | |
| Philadelphia, PA | 2 | Lead | Jan 2014 | |
| New York City, NY | 2 | Participant | Feb 2019 | |
| Boston, MA | 2 | Participant | Jan 2018 | |
| New York City, NY | 2 | Lead | Jun 2020 | |
 Shanghai | 1 | Lead | Apr 2015 | |
| Seattle, WA | 1 | Participant | Jan 2018 | |
| New York City, NY | 1 | Lead | Mar 2022 | |
This data is available for Pro users. Sign up to see all 14 DNAnexus investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialDNAnexus Competitors
DNAnexus competitors include listed companies like Baudroie and Plus Alpha Consulting, and private ones like PicnicHealth, SkyCell, David AI and groundcover.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| San Francisco, CA | Private | $61M | - | $410M | 6.7x | |
 Zurich | Private | - | - | $635M | - | |
| San Francisco, CA | Private | - | - | $500M | - | |
 Tel Aviv | Private | - | - | $500M | - | |
 Japan | Publicly listed | $112M | $24M | $595M | 4.3x | |
| Japan | Publicly listed | $110M | $36M | $572M | 3.8x |
DNAnexus Public Comps
DNAnexus is still privately-owned, but its public comps include Baudroie, Plus Alpha Consulting, OmniAb, Edarat Group, Consensus Cloud, Veradigm, Whitefiber, Inspur, Napatech and Avacta Group.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $112M | $24M | 5.2x | 4.3x | 24.7x | 21.0x | |||
| $110M | $36M | 4.2x | 3.8x | 12.9x | 9.4x | |||
| $19M | ($47M) | 32.8x | 20.2x | (13.0x) | (18.4x) | |||
| $51M | $12M | 10.6x | - | 44.5x | - | |||
| $350M | $166M | 3.2x | 3.1x | 6.8x | 5.9x | |||
| $588M | $54M | 0.9x | 0.9x | 9.8x | 6.8x | |||
| $79M | ($2M) | 12.1x | 7.9x | (412.2x) | 25.8x | |||
| $172M | ($31M) | 3.7x | 2.7x | (20.3x) | - | |||
This data is available for Pro users. Sign up to see all DNAnexus competitors and their valuation data. Start Free Trial | ||||||||
Common questions about DNAnexus
| When was DNAnexus founded? | DNAnexus was founded in 2009. |
| Where is DNAnexus headquartered? | DNAnexus is headquartered in San Francisco, CA, United States. |
| Is DNAnexus publicly listed? | No, DNAnexus is a private, VC-backed company. |
| What is DNAnexus' valuation? | DNAnexus was last valued at $600M in its Series H in March 2022. |
| How much funding has DNAnexus raised? | DNAnexus has raised $456M across 6 funding rounds. |
| What was DNAnexus' last funding round? | DNAnexus' last funding round was a $200M Series H in March 2022, led by Blackstone. |
| Who are DNAnexus' investors? | DNAnexus' investors include GV, Foresite Capital, TPG, Claremont Creek Ventures, Northpond Ventures, First Round Capital, Innovatus Capital Partners, Genuity Science, Perceptive Advisors, Wuxi AppTec and 4 others. |
| Which companies are comparable to DNAnexus? | Companies comparable to DNAnexus include PicnicHealth, SkyCell, David AI, groundcover, Baudroie and Plus Alpha Consulting. |
See companies similar to DNAnexus
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.